Bacteremia
3
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
BP
Basilea PharmaceuticaSwitzerland - Allschwil
1 program1
ceftobiprole medocarilPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
PfizerCefazolin IV
Basilea Pharmaceuticaceftobiprole medocaril
Armata PharmaceuticalsAP-SA02
ExThera MedicalSeraph 100 Filter
Clinical Trials (4)
Total enrollment: 126 patients across 4 trials
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
Start: Sep 2005Est. completion: Sep 200661 patients
Phase 3Terminated
Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus Bacteremia
Est. completion: Apr 2009
Phase 2Withdrawn
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
Start: Apr 2022Est. completion: Jan 202550 patients
Phase 1/2Completed
Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis
Start: Feb 2016Est. completion: Jun 201815 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space